ChiCTR2500101726 版本V1.0 版本创建时间2025/04/29 10:10:27 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500101726 

最近更新日期:

Date of Last Refreshed on:

2025-04-29 10:10:20 

注册时间:

Date of Registration:

2025-04-29 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

基于人工智能图像识别及远程医疗开展我市糖尿病患者糖尿病视网膜病变筛查及随访治疗的研究

Public title:

Study on the establishment of diabetic retinopathy screening and follow-up treatment for diabetic patients in our city based on artificial intelligence image recognition and telemedicine

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于人工智能图像识别及远程医疗开展我市糖尿病患者糖尿病视网膜病变筛查及随访治疗的研究

Scientific title:

Study on the establishment of diabetic retinopathy screening and follow-up treatment for diabetic patients in our city based on artificial intelligence image recognition and telemedicine

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张妍春 

研究负责人:

张妍春 

Applicant:

Zhang Yanchun 

Study leader:

Zhang Yanchun 

申请注册联系人电话:

Applicant telephone:

+86 189 9288 8336

研究负责人电话:

Study leader's
telephone:

+86 189 9288 8336

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zhangyanchun1239@126.com

研究负责人电子邮件:

Study leader's E-mail:

zhangyanchun1239@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

陕西省西安市解放路21号

研究负责人通讯地址:

陕西省西安市解放路21号

Applicant address:

No. 21, Jiefang Road, Xi'an, Shaanxi Province

Study leader's address:

No. 21, Jiefang Road, Xi'an, Shaanxi Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

西安市人民医院(西安市第四医院)

Applicant's institution:

Xi'an People's Hospital (Xi'an No. 4 Hospital)

研究负责人所在单位:

西安市人民医院(西安市第四医院)

Affiliation of the Leader:

Xi'an People's Hospital (Xi'an No. 4 Hospital)

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

20220066

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

西安市人民医院(西安市第四医院)伦理委员会

Name of the ethic committee:

The ethic committee of Xi'an People's Hospital (Xi'an No. 4 Hospital)

伦理委员会批准日期:

Date of approved by ethic committee:

2022-05-11 00:00:00

伦理委员会联系人:

王曼

Contact Name of the ethic committee:

Wang Man

伦理委员会联系地址:

陕西省西安市解放路21号

Contact Address of the ethic committee:

No. 21, Jiefang Road, Xi'an, Shaanxi Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 150 0298 6763

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

西安市第四医院

Primary sponsor:

Xi 'an Fourth Hospital

研究实施负责(组长)单位地址:

陕西省西安市解放路21号

Primary sponsor's address:

No. 21, Jiefang Road, Xi'an, Shaanxi Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

陕西

市(区县):

Country:

China

Province:

Shaanxi

City:

单位(医院):

西安市第四医院

具体地址:

陕西省西安市解放路21号

Institution
hospital:

Xi 'an Fourth Hospital

Address:

No. 21, Jiefang Road, Xi'an, Shaanxi Province

经费或物资来源:

西安市科技局项目和西安市人民医院(西安市第四医院)院基金

Source(s) of funding:

Xi'an Science and Technology Bureau Project and Xi'an People's Hospital (Xi'an No. 4 Hospital) Hospital Foundation

研究疾病:

糖尿病视网膜病变  

Target disease:

Diabetic retinopathy

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

(1)筛选更适合国情的DR筛查的眼底数字照相方法及AI算法。 (2)建立符合我市开展的融DR筛查、治疗及随访为一体的主动医疗体系。 (3)对西安地区糖尿病患者DR发病情况、影响因素、进展情况等进行流调学分析。 (4)分析研究糖尿病患者血液、尿液中的生物学指标与DR、DME,糖尿病干眼、糖尿病肾病的发生、发展是否具有相关性。  

Objectives of Study:

(1) Screening the fundus digital photography method and AI algorithm which are more suitable for DR screening in China. (2) Establish an active medical system that integrates DR screening, treatment and follow-up in our city. (3) Epidemiological analysis was made on the incidence, influencing factors and progress of DR among diabetic patients in Xi 'an. (4) Analyze whether the biological indexes in blood and urine of diabetic patients are related to the occurrence and development of DR, DME, diabetic dry eye and diabetic nephropathy.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

西安市辖区(城区及郊区/县)≥35岁的建有慢性病档案的糖尿病患者。

Inclusion criteria

Diabetic patients aged 35 or above with chronic disease files in Xi 'an municipal districts (urban areas and suburbs/counties).

排除标准:

西安市辖区(城区及郊区/县)年龄<35岁的糖尿病患者。

Exclusion criteria:

Diabetic patients < 35 years old in Xi 'an district (urban area and suburban area/county).

研究实施时间:

Study execute time:

From 2022-05-12 00:00:00 To 2025-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-06-24 00:00:00 To 2024-12-31 00:00:00

干预措施:

Interventions:

组别:

糖尿病患者组

样本量:

16651

Group:

Diabetic patients group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

陕西 

市(区县):

 

Country:

China

Province:

Shaanxi

City:

单位(医院):

西安市第四医院 

单位级别:

三甲 

Institution
hospital:

Xi'an No. 4 Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

视网膜荧光造影

指标类型:

次要指标

Outcome:

Retinal Fluorescence Angiography (FFA)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

光学相干断层

指标类型:

次要指标

Outcome:

Optical coherence tomography

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血脂

指标类型:

次要指标

Outcome:

Blood lipid

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胱抑素C

指标类型:

次要指标

Outcome:

Cystatin c

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血压

指标类型:

次要指标

Outcome:

Blood Pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

糖化血红蛋白A1c

指标类型:

主要指标

Outcome:

HbA1c

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

眼底照相

指标类型:

主要指标

Outcome:

Fundus photography

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿微量白蛋白

指标类型:

主要指标

Outcome:

Urine microalbumin

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿肌酐

指标类型:

次要指标

Outcome:

Urine creatinine

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 35 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2045年1月1日 国家人口与健康科学数据共享临床医学科学数据中心(http://www.ncmi.cn)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

January 1, 2045 National Population and Health Sciences Data Sharing Clinical Medical Sciences Data Center (http://www.ncmi.cn)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

EDC系统(https://xian.gausscloud.com/Views/login/login.html)

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic Data Capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-04-29 10:10:20